Luyan Pharma Co Ltd

Luyan Pharma released its 2026 interim report, with net profit attributable to the parent company of 143 million yuan, down 7.46% from the same period last year. Total operating revenue was 10.583 billion yuan, up 1.75% year on year, marking a fifth consecutive year of growth. Net cash flow from operating activities was negative 101 million yuan, down 147.98% from the same period last year. The company's latest asset-liability ratio was 74.77%, gross margin was 6.84%, return on equity was 4.32%, and diluted earnings per share was 0.37 yuan.

Luyan Pharmaceutical released its 2026 semi-annual report. In the first half, net profit attributable to shareholders was about 143 million yuan, down 7.46% year-on-year. During the same period, the company achieved operating revenue of about 10.583 billion yuan, up 1.75% year-on-year. Luyan Pharmaceutical is mainly engaged in the distribution of pharmaceuticals, Chinese herbal medicine pieces, medical devices and other products, as well as retail pharmacy chain operations, with pharmaceutical wholesale being the main source of the company's revenue.